News | Image Guided Radiation Therapy (IGRT) | August 07, 2017

Early Clinical Experience with ViewRay's MRIdian Linac Presented at AAPM 2017

Talks highlight clinical value of MRIdian on-table adaptive therapy for escalating target dose and avoiding nearby organs at risk

August 7, 2017 — ViewRay Inc. announced that several presentations of early clinical experience with its MRIdian Linac technology were made at the 2017 annual meeting of the American Association of Physicists in Medicine (AAPM), July 30-Aug. 2 in Denver. MRIdian Linac is the world’s only U.S. Food and Drug Administration (FDA)-cleared magnetic resonance imaging (MRI)-guided radiation therapy system with linear accelerator-based delivery, according to the company.

The company's MRIdian System was the focus of 30 abstracts selected by AAPM, including several talks describing the significant advantages of daily on-table adaptive radiation therapy and its positive clinical impact on treatment. MR-guided on-table adaptive therapy allows for dose escalation for stereotactic body radiation therapy (SBRT) treatments and dose de-escalation in cases where the critical structures are too close to the tumor. 

The AAPM Scientific Session talks also highlighted MRIdian's fully integrated workflow for adaptive therapy, which incorporates complete Monte Carlo dose replanning to account for changes in the shape and position of the tumor and adjacent organs in less than two minutes.

ViewRay featured a number of presentations in the company's booth given by MRIdian users from five top cancer centers: Henry Ford Health System in Metro Detroit; University of California, Los Angeles; Washington University in St. Louis; University of Wisconsin; and University of Miami.

Highlights from these talks included:

  • Carri Glide-Hurst, Ph.D., from Henry Ford presented on their initial patient experience with MRIdian Linac including treatment times of 6.25 minutes for 8Gy SBRT treatments and 5 minutes for prostate intensity modulated radiation therapy (IMRT) treatments. She also showed MRIdian movies on how the system's real-time imaging during treatment automatically detected and paused the treatment when a transient gas bubble shifted the prostate. Additional patients in the queue for Henry Ford include liver SBRT, retroperitoneal SBRT and accelerated partial breast irradiation (APBI). "MRIdian really does take the blindfold off in showing us things we've never seen before," said Glide-Hurst. "We're now able to treat indications that we hadn't really treated previously like APBI. We're excited about the potential of reducing margins and getting a conformal delivery with MRI guidance";
  • Anthony Doemer, M.S., from Henry Ford highlighted the ultra-sharp beam characteristics for the RayZR Double focused multileaf collimator (MLC). Because of its design, it removes the need for tongue and grooves, nearly eliminating any leakage through the leaves (average leakage, less than 0.001 percent). "We were able to successfully commission the MLC with great agreement between measured small beam profiles of 0.2 x 0.4 cm and larger profiles matching very well with the Monte Carlo simulations with tight conformance to the beam model," said Doemer;
  • Yingli Yang, Ph.D., from UCLA presented on MRIdian's high-quality MRI images, specifically the superior soft-tissue image quality enabled by MRIdian's processing techniques. Yang also highlighted early research imaging results acquired using a new MR acquisition technique reducing the imaging times of 17 seconds down to approximately 12 seconds. This 3-D MRI sequence provides motion artifact-free images with a large field of view (FOV) for short breath hold. She also presented research on a 3-D MRI acquisition scheme that is insensitive to motion and will enable free breathing MRI for patients who are unable to hold their breath;
  • Vivian Rodriguez, Ph.D., from Washington University shared their extensive experience with on-table adaptive therapy, illustrating the significant anatomical changes that can take place within a short period of time and highlighting case examples where the treatment plan was reoptimized to escalate or de-escalate dose based upon the proximity of nearby critical structures while the patient was on the treatment table. "With a single button click we can replan within a minute a new treatment plan that reduces dose to organs at risk while giving a greater dose to the target," said Rodriguez; and
  • Kathryn Mittauer, Ph.D., from the University of Wisconsin shared their experience personalizing patient treatments through daily dose-guided radiotherapy using online recalculation and evaluation of the actual dose distribution. "We're able to deliver higher doses to targets adjacent to organs at risk due to improved confidence in treatment set up and delivery that would not otherwise be clinically feasible," said Mittauer.

For more information: www.viewray.com

 

Related Articles on MRI-guided Radiation Therapy:

MRI-guided Radiation Therapy (2017)

First Patients Treated with ViewRay's MRIdian Linac at Henry Ford Health System

Elekta Begins MR-Linac Installation at Sunnybrook Health Sciences Centre

MRI-Guided Radiation Therapy (2016)

MRI Brings New Vision to Radiation Therapy

Dutch Medical Center Begins Installation of World's First High-field MRI-guided Radiation Therapy System

Related Content

Videos | Image Guided Radiation Therapy (IGRT) | October 15, 2018
Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute, describes the benefits the departm
Varian Expands Cancer Care Portfolio With Noona Healthcare Acquisition
News | Patient Engagement | October 15, 2018
Varian announced the acquisition of privately-held software company Noona Healthcare, developer of a cloud-based,...
New Guideline for Prostate Cancer Supports Shortened Radiation Therapy
News | Prostate Cancer | October 12, 2018
Three prominent medical societies issued a new clinical guideline for physicians treating men with early-stage prostate...
FDA Clears Magnetom Sola 1.5T MRI From Siemens Healthineers
Technology | Magnetic Resonance Imaging (MRI) | October 09, 2018
The U.S. Food and Drug Administration (FDA) has cleared the Magnetom Sola, a 1.5 Tesla magnetic resonance imaging (MRI...
Surgery, Radiation Therapy Equally Effective in Treating Oropharyngeal Cancer
News | Radiation Therapy | October 09, 2018
A new study by researchers at UT Southwestern Medical Center found no major long-term differences in the effectiveness...
ASTRO 2018 Radiation Therapy Clinical Trials
Feature | ASTRO | October 08, 2018
October 8, 2018 — The American Society for Radiation Oncology (ASTRO) announced the 10 top-rated clinical studies tha
Videos | Treatment Planning | October 08, 2018
Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology at Henry Ford Health System, descri
ViewRay and Miami Cancer Institute Host Symposium on MR-Guided Radiation Therapy
News | Image Guided Radiation Therapy (IGRT) | October 05, 2018
October 5, 2018 — Leading oncology experts from around the world recently met to discuss the integration of...
Videos | Treatment Planning | October 05, 2018
Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology at Henry Ford Health System, descri
Videos | Image Guided Radiation Therapy (IGRT) | October 04, 2018
Carrie Glide-Hurst, Ph.D., and Benjamin Movsas, M.D., discuss Henry Ford Hospital's involvement in a national clinica